Silo Pharma Inc (SILO) Stock Price, Quote & News

Company Profile

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders....

Industry: Biotechnology

Sector: Healthcare

Phone: 718 400 9031

Website: silopharma.com

Address:

677 North Washington Boulevard, Sarasota, United States

SlamminSammmy Jan. 9 at 9:09 PM

$SILO started new position at .33 before new years, I’m liking this so far

0 · Reply

Money_Too_Long Jan. 2 at 5:56 AM

$SILO

1 · Reply

JohnTrack Dec. 30 at 5:29 PM

$SILO watching if dips get bought...

0 · Reply

JohnTrack Dec. 30 at 3:05 PM

$SILO Letter of Intent with Allucent to Support Phase 1 https://www.rapidticker.com/news/silo-silo-pharma-executes-letter-of-e46dc6

0 · Reply

Furnitureslinger Dec. 30 at 1:13 PM

$SILO

0 · Reply

Jbjb90 Dec. 30 at 1:12 PM

$SILO https://www.stocktitan.net/news/SILO/silo-pharma-executes-letter-of-intent-with-allucent-to-support-phase-0oxrrksv2wng.html

0 · Reply

Stock_Catcher Dec. 30 at 1:06 PM

$SILO another one already 22% gainer

0 · Reply

Jbjb90 Dec. 30 at 1:05 PM

$SILO https://www.investing.com/news/sec-filings/silo-pharma-receives-extension-from-nasdaq-to-regain-minimum-bid-price-compliance-93CH-4424094

0 · Reply

Money_Too_Long Dec. 29 at 9:37 PM

$SILO https://www.tradingview.com/news/tradingview:e5f0a255377b3:0-silo-pharma-received-notice-of-noncompliance/

0 · Reply

WiFiWizard Dec. 26 at 1:52 PM

$SILO Expectations are recalibrating toward pragmatic delivery instead of lofty projections. Improving execution cadence across quarters would alter sentiment materially. Momentum could expand quickly if milestones stop slipping. Execution quality will determine whether momentum is sustainable.

0 · Reply

Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

Nov 17, 2025, 8:05 AM EST - 2 months ago

Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD

Oct 29, 2025, 8:25 AM EDT - 2 months ago

Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain

Oct 23, 2025, 8:45 AM EDT - 2 months ago

Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program

Oct 8, 2025, 8:45 AM EDT - 3 months ago

Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth

Oct 6, 2025, 8:10 AM EDT - 3 months ago

Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

Oct 1, 2025, 4:20 PM EDT - 3 months ago

Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 30, 2025, 8:02 AM EDT - 3 months ago

Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 16, 2025, 8:11 AM EDT - 4 months ago

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Sep 9, 2025, 9:10 AM EDT - 4 months ago

Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug

Sep 3, 2025, 8:25 AM EDT - 4 months ago

Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio

Aug 21, 2025, 2:00 PM EDT - 5 months ago

Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal

Aug 19, 2025, 8:05 AM EDT - 5 months ago

Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

Aug 5, 2025, 8:32 AM EDT - 5 months ago

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Jul 16, 2025, 8:45 AM EDT - 6 months ago

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

Jul 7, 2025, 8:15 AM EDT - 6 months ago

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Jun 25, 2025, 8:38 AM EDT - 7 months ago

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Jun 25, 2025, 8:27 AM EDT - 7 months ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

HOTH

Jun 11, 2025, 9:00 AM EDT - 7 months ago

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Jun 5, 2025, 9:15 AM EDT - 7 months ago

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

May 21, 2025, 8:55 AM EDT - 8 months ago

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

May 16, 2025, 4:15 PM EDT - 8 months ago

Silo Pharma Announces Closing of $2 Million Public Offering

May 15, 2025, 9:15 AM EDT - 8 months ago

Silo Pharma Announces Pricing of $2 Million Public Offering

May 14, 2025, 4:07 PM EDT - 8 months ago

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

May 14, 2025, 8:40 AM EDT - 8 months ago

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

Apr 30, 2025, 8:11 AM EDT - 9 months ago

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Apr 28, 2025, 7:50 AM EDT - 9 months ago

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Mar 26, 2025, 8:40 AM EDT - 10 months ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Feb 26, 2025, 1:30 PM EST - 11 months ago

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Feb 18, 2025, 8:50 AM EST - 11 months ago

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Feb 11, 2025, 7:45 AM EST - 1 year ago

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Jan 22, 2025, 8:29 AM EST - 1 year ago

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Jan 2, 2025, 8:45 AM EST - 1 year ago

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Dec 18, 2024, 7:35 AM EST - 1 year ago

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Nov 29, 2024, 8:05 AM EST - 1 year ago

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Nov 18, 2024, 8:40 AM EST - 1 year ago

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Oct 31, 2024, 8:35 AM EDT - 1 year ago

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Sep 10, 2024, 6:35 AM EDT - 1 year ago

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Aug 14, 2024, 2:30 PM EDT - 1 year ago

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Aug 7, 2024, 8:13 AM EDT - 1 year ago

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Jul 26, 2024, 8:20 AM EDT - 1 year ago

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Jul 22, 2024, 4:45 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 19, 2024, 8:01 AM EDT - 1 year ago

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 18, 2024, 12:44 PM EDT - 1 year ago

Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug

Jul 18, 2024, 8:25 AM EDT - 1 year ago

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Jul 16, 2024, 10:50 AM EDT - 1 year ago

Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?

Jul 16, 2024, 6:30 AM EDT - 1 year ago

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

Jun 26, 2024, 8:50 AM EDT - 1 year ago

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

Jun 7, 2024, 8:18 AM EDT - 1 year ago

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

Jun 6, 2024, 4:50 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SlamminSammmy Jan. 9 at 9:09 PM

$SILO started new position at .33 before new years, I’m liking this so far

0 · Reply

Money_Too_Long Jan. 2 at 5:56 AM

$SILO

1 · Reply

JohnTrack Dec. 30 at 5:29 PM

$SILO watching if dips get bought...

0 · Reply

JohnTrack Dec. 30 at 3:05 PM

$SILO Letter of Intent with Allucent to Support Phase 1 https://www.rapidticker.com/news/silo-silo-pharma-executes-letter-of-e46dc6

0 · Reply

Furnitureslinger Dec. 30 at 1:13 PM

$SILO

0 · Reply

Jbjb90 Dec. 30 at 1:12 PM

$SILO https://www.stocktitan.net/news/SILO/silo-pharma-executes-letter-of-intent-with-allucent-to-support-phase-0oxrrksv2wng.html

0 · Reply

Stock_Catcher Dec. 30 at 1:06 PM

$SILO another one already 22% gainer

0 · Reply

Jbjb90 Dec. 30 at 1:05 PM

$SILO https://www.investing.com/news/sec-filings/silo-pharma-receives-extension-from-nasdaq-to-regain-minimum-bid-price-compliance-93CH-4424094

0 · Reply

Money_Too_Long Dec. 29 at 9:37 PM

$SILO https://www.tradingview.com/news/tradingview:e5f0a255377b3:0-silo-pharma-received-notice-of-noncompliance/

0 · Reply

WiFiWizard Dec. 26 at 1:52 PM

0 · Reply

Money_Too_Long Dec. 23 at 3:44 PM

$SILO Well I’m out let’s see what’s next

0 · Reply

Money_Too_Long Dec. 22 at 6:31 PM

$SILO As soon as I start shorting this thing trying to edge up. 😬

0 · Reply

Money_Too_Long Dec. 19 at 6:36 PM

$SILO As soon as this dip to .30 I’m going big 🚀🚀🚀🚀🚀🚀NFA

0 · Reply

Money_Too_Long Dec. 18 at 9:34 PM

$SILO Almost time for seasonal stock rally Load Up NFA🚀🚀🚀🚀🚀

1 · Reply

CEOBuysDisclosures Dec. 17 at 1:40 AM

$SILO CEO purchased 5,000 shares at $0.41 for a total of $2,075. Weisblum Eric now owns 216,932 shares. https://ceo-buys.com

0 · Reply

Love_To_Learn Dec. 12 at 12:21 AM

$SILO need u soon

1 · Reply

Money_Too_Long Dec. 9 at 1:14 AM

$SILO This mf boiling ready to hit .85 and blast off.

1 · Reply

Money_Too_Long Dec. 8 at 8:27 PM

$SILO This thing ready to pop.

1 · Reply

TaySwift Dec. 3 at 8:13 PM

$SILO So: 🔹 No IND has been submitted yet. 🔹 IND-enabling data is still being generated. 🔹 The company itself is telling us: “we expect to submit in 2026” On Oct 24, 2025, shareholders approved giving the board power to do a reverse split between 1-for-2 and 1-for-20 any time before Oct 24, 2026, to help keep Nasdaq listing. $2.5M registered direct offering at $0.875 with attached warrants in Oct 2025. New 424B3 prospectus filed Nov 26, 2025 registering ~3.07M shares for resale by selling securityholders.

2 · Reply

MGeronimo Dec. 3 at 5:40 PM

$SILO AIF IT BREAKS .85 she will run up

1 · Reply

MGeronimo Dec. 3 at 5:39 PM

$SILO going to run up

0 · Reply

Money_Too_Long Nov. 28 at 9:21 PM

$SILO Something is brewing.

1 · Reply

Market Cap	5.13M
Revenue (ttm)	70,000.00
Net Income (ttm)	-4.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,271.43%
Debt to Equity Ratio	0.00

Volume	46,800
Avg Vol	152,226
Day's Range	N/A - N/A
Shares Out	13.32M
Stochastic %K	70%
Beta	0.44
Analysts	Strong Sell
Price Target	$10.00